Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
How, if at all, do you use changes in SUV on a PET-CT to assess for disease progression/response in patients with metastatic breast cancer?
Related Questions
How are you considering use of inavolisib/palbociclib/fulvestrant over ET doublets for patients with high risk disease features such as visceral metastases, visceral crisis, high tumor burden?
How will you weigh the positive PFS but negative OS benefit when discussing Dato-DXd with patients?
What supportive care measures do you prioritize to manage or prevent toxicity in patients receiving Dato-DXd?
In a patient with metastatic PIK3CA-mutant, HR-positive, HER2-low breast cancer who is intolerant to capivasertib, would you preferentially use another PIK3 inhibitor or switch to T-DXd?
How will you sequence Dato-DXd among available therapies for HR positive, HER2-0 metastatic breast cancer?
For an elderly woman with de novo metastatic HER2+ breast cancer with lung and brain mets, how would you approach her treatment, especially now with data from DESTINY-Breast 09 data?
Is there any benefit of anastrozole in addition to fulvestrant and palbociclib in a patient with HR+ metastatic breast cancer?
What are your top takeaways in Medical Oncology from SABCS 2025?
For metastatic ER+ HER2-negative breast cancer treatment, how do you select between imlunestrant (plus or minus abemaciclib) and elacestrant for those with an ESR1 mutation and progressed on AI and CDK 4/6 inhibitor?
What adjuvant therapy would you offer a postmenopausal with a new pT2N0 HR+/HER2+ breast cancer primary who is concurrently being treated for well controlled oligometastatic HR+/HER2- who’s been on anastrozole/ribociclib?
